Recent study evaluated hemolysis in patients supported with the Impella 5.5 percutaneous left ventricular assist device in a single-center experience. The research aimed to characterize the hemolytic ...

For circulatory support in cardiogenic shock, the best choice between Impella and intra-aortic balloon pump (IABP) has been controversial. Now, new data is complicating the debate. Presenting at ...

Explaining the two cases, Dr Brajesh Kunwar said, "In the first case, it was a 24-year-old woman called Pooja, who was admitted at 2AM one night with a diagnosis of massive pulmonary embolism. In ...

Medical Technology and Life Science Ventures II: Team Veina Vascular, a medical device that optimizes blood collection in emergency departments to reduce hemolysis (the premature breakdown of red ...

Joaquin Duato; Chairman of the Board, Chief Executive Officer; Johnson & Johnson John Reed; Executive Vice President - Innovative Medicine, Research and Development; Johnson & Johnson Joseph Wolk ...

These included updates to the American College of Cardiology and American Heart Association guidelines for our Impella heart pump, which based on evidence from the DANGER shock trial was upgraded ...

Anand Viswanathan, MD, had a sinking suspicion he couldn’t quite explain. His patient had unexplained abdominal pain a few days after getting a feeding tube. Imaging showed nothing and vital ...

Joaquin Duato; Chairman of the Board, Chief Executive Officer; Johnson & Johnson John Reed; Executive Vice President - Innovative Medicine, Research and Development; Johnson & Johnson Joseph Wolk; ...

In patients with cardiogenic shock (CS), a percutaneous microaxial ventricular assist device (Impella, Abiomed, Danvers, MA) is a choice for temporary mechanical circulatory support. Given the high ...

In patients undergoing high‐risk percutaneous coronary intervention, Impella has become an important adjunctive tool to support revascularization. The impact of age on the outcomes of patients ...